Diabetes lecture 2 Flashcards

1
Q

Biguanide

A

Metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

SGLT2 inhibitors

A

Canagliflozin
Dapagliflozin
Empagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

GLP-1 receptor agonist

A

Exenatide
Liraglutide
Dulaglutide
Semaglutide (Ozempic (Sc) and Rybelsus (PO)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Sulfonylureas

A

Glyburide

Glipizide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Non-SU secretagogues

A

Repaglinide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

DPP4 inhibitors

A

Sitagliptin
Saxagliptan
Linagliptin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

TZDs

A

Pioglitazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Metformin MOA

A

decreases hepatic glucose output, lowing fasting BG levels

enhances insulin sensitivity of both hepatic and muscle tissue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metformin efficacy

A

lowers A1C 1-1.5%

weight loss

does not cause hypoglycemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Metformin ADE

A

GI –> diarrhea, cramping, bloating
ER formulation –> less GI effects

Vitamin B 12 deficiency

Lactic acidosis -rare

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Metformin (when to not use)

A

known hypersensitivity

surgical procedures

alcohol abuse

liver dysfunction

Significant renal disease

iodinated contrast media (GFR < 60)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Metformin and renal insufficiency

A

GFR > 60 –> ok
GFR 45-59 –> ok
GFR 30-44 –> metformin shouldn’t be started but can be continued
GFR < 30 –> do not use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Metformin dosing

A

usual dose is 1000 mg BID

500 or 850 mg po daily (with largest meal)
500mg po BID (with two largest meals)

if no GI effects, increase every 1-2 wks to max dose of 2000-25500mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Metformin ER

A

given once daily
500, 750, 1000 ER tabs

titrate to 2000mg/daily

if taking 750 tab, max dose is 1500mg/day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Metformin monitoring

A

Counsel on adherence
A1c, renal function, vit B12
SMBG readings
take with meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Advantages of metformin

A
 Shown to reduce macrovascular 
complications in obese pts
 Other oral agents are not more 
effective in reducing HbA1c 
 Does not cause hypoglycemia when 
used as monotherapy
 Does not cause weight gain (may be 
a/w weight loss of about 6 lb)
Helps minimize weight gain with other 
agents
 Inexpensive
 Should see effects on BG within a week
 Comes in combination pills with many 
other oral agents
17
Q

Disadvantages of metformin

A
 GI adverse effects 
 It is a large pill to swallow
 Metformin generally given BID 
 Metformin ER given QD, but require 
multiple pills at the same time
 Risk of lactic acidosis  - RARE
 Monitor for renal insufficiency
 Monitor for vit B12 deficiency
18
Q

If A1c target is not achieved in about 3

months with metformin monotherapy,

A
add a second agent while: 
 Re-emphasizing lifestyle measures 
 Assessing adherence / access to 
medications
 Arranging routine follow-up
19
Q

Second line therapy:

ASCVD

A

GLP and/or SGLT2 i

20
Q

Second line therapy:

HF

A

SGLT2i

21
Q

Second line therapy:
CKD
elevated UACR

A

SGLT2i preferred or GLP

22
Q

Second line therapy:
CKD
no elevated UACR

A

GLP and/or SGLT2i

23
Q

Agents to avoid in HF

A

Pioglitazone

Saxagliptan

24
Q

Highest A1C efficacy

A

GLP-1 receptor

25
Q

Weight loss

A

SGLT2 i

GLP-1

26
Q

only one with risk of hypoglycemia

A

Sulfonylureas

27
Q

Drugs that target fasting blood glucose

A

metformin
basal insulin
NPH insulin

28
Q

Drugs that target post prandial BG levels

A

DPP-4 inhibitors
Exenatide
Regalinide
Prandial insulin

29
Q

Drugs that have mixed BG level targets

A
Sulfonylureas 
long acting GLP-1 RA
TDZ
SGLT2i
mixed insulins